Disease · EFO_0009516

burn

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. burn. Diseases, record EFO_0009516. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009516

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: burn; Open Targets
Open Targets ID: EFO_0009516; Open Targets
NCI Thesaurus: C34441; NCI Thesaurus
Highest stage of its drugs: Approval, for 17 of its 43 drugs, from DailyMed and PMDA; Open Targets

Drugs43

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Source
BACITRACIN	CHEMBL1200558	Protein	Approval	DailyMed	10	Drugs and targets
NEOMYCIN SULFATE	CHEMBL3989769		Approval	DailyMed	8	Drugs and targets
LIDOCAINE	CHEMBL79	Small molecule	Approval	DailyMed	6	Drugs and targets
ZINC OXIDE	CHEMBL3988900	Small molecule	Approval	DailyMed	6	Drugs and targets
BENZOCAINE	CHEMBL278172	Small molecule	Approval	DailyMed	5	Drugs and targets
PRAMOXINE HYDROCHLORIDE	CHEMBL1201171	Small molecule	Approval	DailyMed	4	Drugs and targets
POVIDONE-IODINE	CHEMBL1201724		Approval	DailyMed	3	Drugs and targets
DIPHENHYDRAMINE HYDROCHLORIDE	CHEMBL1620	Small molecule	Approval	DailyMed	2	Drugs and targets
MENTHOL	CHEMBL256087	Small molecule	Approval	DailyMed	2	Drugs and targets
ALCOHOL	CHEMBL545	Small molecule	Approval	DailyMed	1	Drugs and targets

1 to 10 of 43

See all 43 drugs

Targets150

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator	Phase 2	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 150

See all 150 targets

Trials23

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02148705	A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns	Phase 3	175	2023-06-27	Thermal Burns	STEM BROMELAIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT02278718	A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care	Phase 3	145	2024-09-27	Thermal Burns	STEM BROMELAIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT04138394	VItamin C in Thermal injuRY: The VICToRY Trial	Phase 3	666		Shock, Thermal Burn	ASCORBIC ACID	Its record names the disease	ClinicalTrials.gov
NCT06968559	Effect of Early Dexamethasone on Major Complications and All-cause Mortality in Severe Burns	Phase 3	478		Severe Burns	DEXAMETHASONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04530058	The Effects of Metformin on Morbidity and Mortality in Elderly Patients	Phase 2	250		Burns	METFORMIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT03590873	The Effect of Restrictive Fluid and Vasopressin During Surgery of Burn Patients	Not applicable	158		Burn Surgery	VASOPRESSIN	Its record names the disease	ClinicalTrials.gov
NCT05805553	Anabolic Steroid and Propranolol in Paediatric Burn	Not applicable	114		Arrest, Bone, Development, Growth	NANDROLONE DECANOATE, PROPRANOLOL	Its record names the disease	ClinicalTrials.gov
NCT04356859	The Acute Burn ResUscitation Multicenter Prospective Trial	Not applicable	101		Burn Injury	ALBUMIN HUMAN	Its record names the disease	ClinicalTrials.gov
NCT05241912	Supernormal Oxygen Delivery for Patients With Severe Burns	Early phase 1	100		Burn Surgery, Dobutamine	DOBUTAMINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT06224777	Comparison of Fluid Resuscitation in Pediatric Burn Patients Using Crystalloids and With Albumin on Day Two.	Phase 2/3	90		Burns	ALBUMIN HUMAN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 23

See all 23 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
NexoBrid Gel vs Standard of Care (SOC): Secondary Endpoint: Number of Participants With Surgical Excision Performed or Eschar Removal for NexoBrid vs SOC (FAS)	3 of 75	54 of 75	150	NCT02148705	Trial comparisons
NexoBrid Gel vs Standard of Care (SOC): Incidence of Surgical Excision Performed for Eschar Removal	6 of 72	47 of 73	145	NCT02278718	Trial comparisons
NexoBrid Gel vs Standard of Care: deaths from any cause	0 of 69	0 of 70	139	NCT02278718	Trial comparisons
NexoBrid Gel vs Standard of Care: serious adverse events	2 of 69	6 of 70	139	NCT02278718	Trial comparisons
NexoBrid Gel vs Gel Vehicle: Primary Endpoint: Number of Participants With Complete Eschar Removal.	70 of 75	1 of 25	100	NCT02148705	Trial comparisons

Papers from its trials11

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36843581	RESULT	1	PubMed
35953455	RESULT	1	PubMed
35339324	RESULT	1	PubMed
29455032	RESULT	1	PubMed
42337788	DERIVED	1	PubMed
42267875	DERIVED	1	PubMed
40117996	DERIVED	1	PubMed
39721243	DERIVED	1	PubMed
39089770	DERIVED	1	PubMed
37715999	DERIVED	1	PubMed

1 to 10 of 11

See all 11 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0009516

GET https://conductscience.org/api/diseases/v1/EFO_0009516/drugs?page=2

API reference For AI assistants